iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD is a equity ETF from iShares tracking the Nasdaq US Biotechnology index through physical replication. Domiciled in Ireland and launched in 2017, the fund manages about 937 M € and charges a TER of 0.35% — 35 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD competes with 1 other products on the same index (Nasdaq US Biotechnology): it ranks 1st by fund size and 1st by ongoing cost, with a TER of 0.35% against a group median of 0.35%. It has been listed since 2017, 9 years of track record.
On a €10,000 investment the TER costs 35 € a year, and no product in the group costs less.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 40.8% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in USD. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| Vertex Pharmaceuticals Inc | 8.1% |
| Amgen Inc | 7.9% |
| Gilead Sciences Inc | 6.9% |
| Regeneron Pharmaceuticals Inc | 4.5% |
| Alnylam Pharmaceuticals Inc | 2.8% |
| Revolution Medicines Inc | 2.8% |
| Biogen Inc | 2.2% |
| Moderna Inc | 1.9% |
| Illumina Inc | 1.9% |
| argenx NV ADR | 1.8% |
| XETRA | 2B70 | EUR |
| Francoforte | 2B70 | EUR |
| London Stock Exchange | BTEC | USD |
| London Stock Exchange | BTEK | GBP |
| SIX Swiss Exchange | BTEC | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.